NO20001514L - Vitronectin-reseptor-antagonist - Google Patents

Vitronectin-reseptor-antagonist

Info

Publication number
NO20001514L
NO20001514L NO20001514A NO20001514A NO20001514L NO 20001514 L NO20001514 L NO 20001514L NO 20001514 A NO20001514 A NO 20001514A NO 20001514 A NO20001514 A NO 20001514A NO 20001514 L NO20001514 L NO 20001514L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001514A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001514D0 (no
Inventor
Dirk Andries Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001514D0 publication Critical patent/NO20001514D0/no
Publication of NO20001514L publication Critical patent/NO20001514L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20001514A 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist NO20001514L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
PCT/US1998/019949 WO1999015170A1 (fr) 1997-09-24 1998-09-24 Antagoniste du recepteur de vitronectine

Publications (2)

Publication Number Publication Date
NO20001514D0 NO20001514D0 (no) 2000-03-23
NO20001514L true NO20001514L (no) 2000-03-23

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001514A NO20001514L (no) 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (fr)
JP (1) JP2002528380A (fr)
KR (1) KR20010024247A (fr)
CN (1) CN1273529A (fr)
AU (1) AU9577498A (fr)
BR (1) BR9813208A (fr)
CA (1) CA2303846A1 (fr)
HU (1) HUP0003949A2 (fr)
IL (1) IL135189A0 (fr)
NO (1) NO20001514L (fr)
PL (1) PL339413A1 (fr)
TR (1) TR200000792T2 (fr)
WO (1) WO1999015170A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
JP2004521079A (ja) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
JP2004510708A (ja) * 2000-08-30 2004-04-08 ファルマシア・コーポレーション ＧＥＭ置換αｖβ３インテグリンアンタゴニスト
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
EP1443963B1 (fr) 2001-10-22 2014-05-21 The Scripps Research Institute Composes de ciblage d'anticorps
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
EP2441464B1 (fr) 2007-01-18 2014-04-09 Merck Patent GmbH Ligands d'intégrine pour leur utilisation dans le traitement du cancer du colon
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
AU2010231631A1 (en) 2009-03-30 2011-11-10 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
CN103864765B (zh) * 2014-03-05 2016-02-10 天津药物研究院 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (fr) * 1996-10-07 2003-07-23 Smithkline Beecham Corp Procede de stimulation de la formation osseuse

Also Published As

Publication number Publication date
JP2002528380A (ja) 2002-09-03
WO1999015170A1 (fr) 1999-04-01
EP1017387A4 (fr) 2004-08-18
CN1273529A (zh) 2000-11-15
NO20001514D0 (no) 2000-03-23
TR200000792T2 (tr) 2000-09-21
PL339413A1 (en) 2000-12-18
AU9577498A (en) 1999-04-12
HUP0003949A2 (hu) 2001-10-28
IL135189A0 (en) 2001-05-20
EP1017387A1 (fr) 2000-07-12
CA2303846A1 (fr) 1999-04-01
BR9813208A (pt) 2000-08-22
KR20010024247A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
NO20001514L (no) Vitronectin-reseptor-antagonist
NO983002L (no) Vitronectin-reseptor-antagonister
NO20001515L (no) Vitronektin reseptor-antagonist
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
DK0865281T3 (da) Naphthylsubstituerede benzimidazolderivater som antikoagulerende midler
GB0111523D0 (en) Chemical compounds
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
DE60121461D1 (de) Kondensierte pyridoindolderivate
DE122005000041I1 (de) Nukleotidanaloga.
BR9812340A (pt) Antagonistas de receptor de vitronectina
DE69935873D1 (de) 2-Methyl-thieno-benzodiazepin Formulierung
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
AP1534A (en) Vitronectin receptor antagonists.
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
WO1998031704A3 (fr) Antagonistes de tachykinine
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (fr) Antagonistes du recepteur de la proteine s

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application